Retifanlimab

Who we are

  • January 12, 2024
    Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Discover the Art of Dance

Discover the Art of Dance

Whether you prefer ballet, jazz, or hip hop , we have a class for you.